Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CEP-37440
- Development stage
- Phase 1
- Lead developer
- Teva Pharmaceutical Industries
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CEP-37440 is an orally available, small molecule dual kinase inhibitor that selectively targets both anaplastic lymphoma kinase (ALK) and focal adhesion kinase (FAK, also known as PTK2). By inhibiting these kinases, CEP-37440 disrupts ALK and FAK-mediated signal transduction pathways, leading to inhibition of tumor cell growth in cells overexpressing these targets. ALK is a receptor tyrosine kinase implicated in various tumors due to gene rearrangements and dysregulation. FAK is a cytoplasmic tyrosine kinase involved in integrin signaling, promoting tumor cell migration, proliferation, survival, and angiogenesis. Preclinical studies indicate that CEP-37440 has favorable metabolic stability and pharmacokinetics and can penetrate the brain. It has been investigated for the treatment of solid tumors[1][2][3][4][5][6].
- Other names
- Alk-fak inhibitor CEP-374401391712-60-9O3MNS8782HO-3MNS8782HO 3MNS8782H
02
Targets
ALK (Anaplastic lymphoma kinase receptor tyrosine kinase)FAK (Focal adhesion kinase)
Beyond the preview
Go deeper on CEP-37440.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CEP-37440.